Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million Post published:February 1, 2022 Post category:Press Release
Levitee Labs Announces Medical Advisory Board Post published:January 6, 2022 Post category:Press Release
Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada Post published:October 14, 2021 Post category:Press Release
Levitee Labs Announces DTC Eligibility Approval Post published:September 24, 2021 Post category:Press Release
Levitee Labs Commences Trading in U.S. Under Ticker LVTTF Post published:September 9, 2021 Post category:Press Release
Levitee Labs Appoints NIH Physician-Scientist Dr. Fady Hannah-Shmouni as Chief Medical and Scientific Officer Post published:August 5, 2021 Post category:Press Release
Levitee Labs Acquires Five Addiction Clinics in Alberta Post published:July 29, 2021 Post category:Press Release
Levitee Labs Acquires Three Specialized Alberta Pharmacies Post published:July 29, 2021 Post category:Press Release
Levitee Labs Announces Completion of Acquisition of BlockMD Telemedicine Platform Post published:July 28, 2021 Post category:Press Release
Levitee Labs Signs Definitive Agreements to Acquire Clinics, Pharmacies, and a Telemedicine Company in Alberta Post published:July 23, 2021 Post category:Press Release